CAVALIER JASON (Chief Financial Officer) received a stock award from LYRA THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/10/2025ACC: 0000950170-25-004166
Officer· Chief Financial Officer
Since Sep 2021
+420K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
420K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+420K
Price / share
—
Trade value
—
% of position
420.0%
1/8/2025
100K→520K
Total
Net shares
+420K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/8/2025 | A · Award | +420K | — | — | 420.0% | 100K | 520K |
| Total | +420K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported